患有固体恶性瘤的重症患者的短期和长期结果:一项回顾性队列研究
Su Yeon Lee1, Jin Won Huh1, Sang-Bum Hong1
1Department of Pulmonary and Critical Care Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
The Korean journal of internal medicine
|October 22, 2024
概括
进入重症监护室 (ICU) 的重症癌症患者的1年生存率很低,尽管ICU死亡率较低. 了解预后对于对固体恶性瘤患者的ICU入院做出明智决策至关重要.
科学领域:
- 在瘤学瘤学.
- 关键护理医学 关键护理医学
- 公共卫生 公共卫生
背景情况:
- 固体恶性瘤的全球发病率正在上升,需要了解这些患者的重症监护室 (ICU) 结果.
- 癌症患者的非计划性ICU入院在预测预后方面存在独特的挑战.
研究的目的:
- 评估患有固体恶性瘤的ICU患者死亡率的风险因素.
- 评估固体恶性瘤患者在ICU入院后的短期和长期结果.
主要方法:
- 进行了一项回顾性队列研究.
- 从2016年至2022年期间在韩国第三级医疗ICU接受治疗的患有固体恶性瘤的患者收集了数据.
主要成果:
- 在955名ICU患者中,ICU死亡率为23.5%.
- 肺癌,较高的序列器官衰竭评估得分,机械呼吸和脏替代疗法与急症监护室死亡率的增加有关.
- 一年生存率为29.3%,需要机械通风或置换治疗的患者的中位生存率显著下降.
结论:
- 患有固体恶性瘤的重症患者在ICU入院后的1年生存率较差.
- 仔细考虑和知情讨论对于这个患者群体的ICU入院决定至关重要,考虑到短期和长期的预后.
相关概念视频
Cancer Survival Analysis
328
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
328
Cancer Therapies
7.6K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.6K
Kaplan-Meier Approach
102
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
102


